A carregar...
Application of PCSK9 Inhibitors in Practice: Part 2 – The Patient Experience
Protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (PCSK9i) are set to revolutionize the treatment of hypercholesterolemia in the management of atherosclerotic risk, but numerous reports have detailed unprecedented barriers to access for these drugs. To overcome these challenges, our grou...
Na minha lista:
| Publicado no: | Circ Res |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6319384/ https://ncbi.nlm.nih.gov/pubmed/30605414 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCRESAHA.118.314191 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|